Browse > Article

Radioimmunotherapy (I): Development of Radioimmunoconjugates  

Choi, Tae-Hyun (Nuclear Medicine Laboratory, Korean Institute of Radiological & Medical Science)
Lim, Sang-Moo (Nuclear Medicine Laboratory, Korean Institute of Radiological & Medical Science)
Publication Information
Nuclear Medicine and Molecular Imaging / v.40, no.2, 2006 , pp. 66-73 More about this Journal
Abstract
Monoclonal antibodies are designed to bind specifically to certain antigen, give therapeutic effect to the target and to be produced in large scale with homogeneity. The monoclonal antibodies conjugated with radionuclide can deliver therapeutic irradiation to the target, and showed successful results in certain malignancies, which is known as radioimmunotherapy. The target-to-background ratio depends on the antigen expression in the target and normal tissues, which is related to the therapeutic efficacy and toxicity in radioimmunotherapy. For the solid tumor beta-ray energy should be high, but lower beta energy is better for the hematological malignancies. I-l31 is widely used in thyroid cancer with low cost and high availability. Labeling monoclonal antibody with I-131 is relatively simple and reproducible. Some preclinical data for the I-131 labeled monoclonal antibodies including acute toxicity and efficacy are available from already published literatures in KIRAMS, physician sponsored clinical trial protocols using Rituximab, KFDA approved anti-CD20 chimeric monoclonal antibody and I-131 were approved by KFDA and currently are ongoing.
Keywords
radioimmunotherapy; radio isotope; monoclonal antibody; clinical trial;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Stone MJ. Monoclonal antibodies in the prehybridoma era: a brief historical perspective and personal reminiscence. Clin Lymphoma 2001;2:148-54   DOI   ScienceOn
2 Buske C, Dreyling M. Unterhalt MHiddemann W [Monoclonal antibody therapy for malignant lymphoma]. Med Klin (Munich) 2005;100:14-24   DOI
3 Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001;39:195-201   DOI   ScienceOn
4 van Laarhoven HW, Punt CJ. Systemic treatment of advanced colorectal carcinoma. Eur J Gastroenterol Hepatol 2004;16:283-9
5 Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57   DOI   ScienceOn
6 Cilley J, Winter JN. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica 2006;91:113-20
7 DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CFDe, Nardo SJ. $^{67}$Cu-versus $^{131}$I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:533-41
8 Choi CW, Lang L, Lee JT, Webber KO, Yoo TM, Chang HK, et al. Biodistribution of $^{18}$F- and $^{125}$I-labeled anti-Tac disulfide- stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Cancer Res 1995;55:5323-9
9 Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997;44:179-88   DOI
10 Blend MJ, Greager JA, Atcher RW, Brown JM, Brechbiel MW, Gansow OA, et al. Improved sarcoma imaging and reduced hepatic activity with indium-111-SCN-Bz-DTPA linked to MoAb 19-24. J Nucl Med 1988;29:1810-6
11 DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma 2000;1:118-26   DOI   ScienceOn
12 Visser GW, Gerretsen M, Herscheid JD, Snow GBvan, Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993;34:1953-63
13 Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990;31:508-11
14 Behr TM, Gotthardt M, Becker W, Behe M. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg experience. Nuklearmedizin 2002;41:71-9   DOI
15 Griffiths GL, Goldenberg DM, Knapp FF, Jr., Callahan AP, Chang CH, Hansen HJ. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. Cancer Res 1991;51:4594-602
16 John E, Thakur ML, DeFulvio J, McDevitt MR, Damjanov I. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J Nucl Med 1993;34:260-7
17 Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Preclinical evaluation of $^{90}$Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999;15:1017-25
18 DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res 2003;9:4013S-21S
19 Illidge TM, Brock S. Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr Pharm Des 2000;6:1399-418   DOI
20 Lewis MR, Zhang J, Jia F, Owen NK, Cutler CS, Embree MF, et al. Biological comparison of $^{149}$Pm-, $^{166}$Ho-, and $^{177}$Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft- bearing nude mice. Nucl Med Biol 2004;31: 213-23   DOI   ScienceOn
21 Najafi A, Alauddin MM, Sosa A, Ma GQ, Chen DC, Epstein AL, et al. The evaluation of $^{186}$Re-labeled antibodies using N2S4 chelate in vitro and in vivo using tumor-bearing nude mice. Int J Rad Appl Instrum B 1992;19:205-12   DOI   ScienceOn
22 Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in $^{(131)}$I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2005;32:458-69   DOI
23 Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005;54: 11-29   DOI   ScienceOn
24 Kraeber-Bodere F, Mishra A, Thedrez P, Faivre-Chauvet A, Bardies M, Imai S, et al. Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Eur J Nucl Med 1996;23:560-7   DOI   ScienceOn
25 Macklis RM, Kaplan WD, Ferrara JL, Kinsey BM, Kassis AIBurakoff SJ Biodistribution studies of anti-Thy 1.2 IgM immunoconjugates: implications for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1988;15:383-9   DOI   ScienceOn
26 Izard ME, Boniface GR, Hardiman KL, Brechbiel MW, Gansow OA, Walkers KZ. An improved method for labeling monoclonal antibodies with samarium-153: use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid. Bioconjug Chem 1992;3:346-50   DOI
27 Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126-42   DOI   ScienceOn
28 Lee YC, Washburn LC, Sun TT, Byrd BL, Crook JE, Holloway EC, et al. Radioimmunotherapy of human colorectal carcinoma xenografts using $^{90}$Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques. Cancer Res 1990;50:4546-51
29 Kobayashi H, Kao CH, Kreitman RJ, Le N, Kim MK, Brechbiel MW, et al. Pharmacokinetics of $^{111}$In- and $^{125}$I-labeled antiTac single-chain Fv recombinant immunotoxin. J Nucl Med 2000;41:755-62
30 Gregory SA. Selecting patients for treatment with $^{90}$Y ibritumomab tiuxetan (Zevalin). Semin Oncol 2003;30:17-22
31 Davies AJ. A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opin Biol Ther 2005;5:577-88   DOI   ScienceOn
32 Buchsbaum DJ, Lawrence TS. New trends in the use of radioimmunoconjugates for the therapy of cancer. Targeted Diagn Ther 1990;3:215-55
33 Yoo TM, Chang HK, Choi CW, Webber KO, Le N, Kim IS, et al. Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment. J Nucl Med 1997;38:294-300
34 Fink-Bennett DM, Thomas K. $^{90}$Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. J Nucl Med Technol 2003;31:61-8; quiz 69-70
35 Illidge TM, Johnson PW. The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol 2000;108:679-88   DOI   ScienceOn
36 DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, et al. Radiation dosimetry for $^{90}$Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using $^{111}$In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 2000;41:952-8
37 Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, et al. Therapeutic advantages of Auger electron- over beta- emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000;27:753-65   DOI
38 Anderson WT, Strand M. Radiolabeled antibody: iodine versus radiometal chelates. NCI Monogr 1987;149-51
39 Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2004;4:18-26   DOI   ScienceOn
40 Nishihara T, Sawada T, Yamamoto A, Yamashita Y, Ho JJ, Kim YS, et al. Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer. Jpn J Cancer Res 2000;91:817-24   DOI
41 Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, et al. Biodistribution and therapeutic efficacy of $^{(125/131)}$I-, $^{(186)}$Re-, $^{(88/90)}$Y-, or$^{(177)}$Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004;45: 1224-32
42 Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. $^{131}$I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513-24   DOI   ScienceOn
43 Lewington V. Development of $^{131}$I-tositumomab. Semin Oncol 2005;32:S50-6
44 Hamby CV, Chinol M, Manzo C, Ferrone S. Purification by affinity chromatography with anti-idiotypic monoclonal antibodies of immunoreactive monoclonal antibodies following labeling with $^{188}$Re. Hybridoma 1997;16:27-31   DOI   ScienceOn
45 Stimmel JB, Kull FC, Jr. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol 1998;25:117-25   DOI   ScienceOn
46 Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol 2000;27:62-73
47 Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II $^{90}$Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27:766-77   DOI
48 Fani M, Xanthopoulos S, Archimandritis SC, Stratis N, Bouziotis P, Loudos G, et al. Biodistribution and scintigraphic studies of $^{153}$Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy. Anticancer Res 2003;23:2195-9
49 Crudo JL, Edreira MM, Obenaus ER, Chinol M, Paganelli Gde Castiglia SG Optimization of antibody labeling with rhenium-188 using a prelabeled MAG3 chelate. Int J Pharm 2002;248:173-82   DOI   ScienceOn
50 van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GBvan, Dongen GA. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 1997;80:2360-70   DOI   ScienceOn
51 Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004;48:251-7
52 Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292-302   DOI   ScienceOn
53 Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, et al. Biodistribution and kinetics of $^{(131)}$I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276-82   DOI   ScienceOn
54 Wurflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, et al. Evaluating antibodies for their capacity to induce cell- mediated lysis of malignant B cells. Cancer Res 1998;58:3051-8
55 Behr TM, Sgouros G, Vougiokas V, Memtsoudis S, Gratz S, Schmidberger H, et al. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of $^{125}$I- vs. $^{131}$I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998;76:738-48   DOI   ScienceOn
56 Fani M, Vranjes S, Archimandritis SC, Potamianos S, Xanthopoulos S, Bouziotis P, et al. Labeling of monoclonal antibodies with $^{153}$Sm for potential use in radioimmunotherapy. Appl Radiat Isot 2002;57:665-74   DOI   ScienceOn
57 Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med 1996;37:1504-10
58 DeNardo GL, Raventos A, Hines HH, Scheibe PO, Macey DJ, Hays MT, et al. Requirements for a treatment planning system for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1985;11:335-48   DOI   ScienceOn
59 Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94:1363-72   DOI   ScienceOn